6533b7defe1ef96bd1276694

RESEARCH PRODUCT

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Robert A. SchwartzStephan GrabbeMartin KassirIndrashis PodderMohamad GoldustMohamad GoldustMohamad GoldustKomal AgarwalYan ValleGhasem Rahmatpour RokniAleksandra VojvodicTorello LottiUwe Wollina

subject

medicine.medical_specialtybusiness.industryVitiligoMEDLINETreatment optionsDermatologyGeneral MedicineVitiligomedicine.diseaselaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallaw030220 oncology & carcinogenesisQuality of LifemedicineHumansImmunologic FactorsProspective StudiesIntensive care medicinebusinessPUVA Therapy

description

Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as "vitiligo," "treatment," "recent," and "immunomodulators" to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.

yearjournalcountryeditionlanguage
2020-01-12Dermatologic Therapy
https://doi.org/10.1111/dth.13215